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Abstract nmd, a novel gene, was isolated by applying the 
differential mRNA display method to human melanoma cell lines 
with different metastatic capacity. In a panel of 17 other human 
tumor cell lines, nmd RNA expression could only be detected at 
low levels in T24 (bladder carcinoma) and Caco-2 (colon 
adenocarcinoma). Furthermore, it was found in placenta and 
liver, but not in skin, colon, spleen, lung, muscle, prostate and 
kidney. Sequence analysis classified the nmd gene product as a 
new member of the enzyme family of lipases (almost 30% identity 
in amino acid sequence with other human lipases). Active site 
residues of lipases were conserved in N M D , but N M D lacks the 
regulatory lid domain, which controls entry to the active site in 
classical lipases. A similar deletion was earlier reported by others 
in the guinea pig pancreatic (phospho)lipase GPLRP2 and the 
phospholipase A l from hornet venom (Dolml). 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The availability of excised lesions as well as cultured cells 
from different stages has made human cutaneous melanoma 
particularly suitable for studies of tumor progression [1]. 
Many changes in gene expression during progression of mel-
anoma have been characterized (for a review see Weterman et 
al. [2]). The use of molecular markers in tumor diagnosis has 
become common practice. Moreover, identification of the 
function of various differentially expressed genes enhances 
our insight in tumor biology. Recently, we have applied the 
differential m R N A display technique on a panel of well-de-
fined [3] human melanoma cell lines with different metastatic 
capacity when xenografted into nude mice. Thus, we isolated 
nine differentially expressed cDNAs, five of which represented 
novel gene products [4]. In this report we describe the char-
acterization of one of them, nmd, encoding an unknown mem-
ber of the enzyme family of lipases. The predicted N M D 
polypeptide lacks a so-called 'lid' domain, as was earlier de-
scribed for guinea pig pancreatic (phospho)lipase G P L R P 2 
and the phospholipase A l from hornet venom (Dolml) [5,6]. 
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2. Materials and methods 
2.1. Biological materials 
Human melanoma cell lines MV3, BLM, 530 and 1F6 [3,7], T24 
bladder carcinoma, PC-3 prostate adenocarcinoma, HeLa cervix car-
cinoma, MCF7 breast adenocarcinoma, Caco-2 colon adenocarcino-
ma, A-431 epidermoid carcinoma, HT-1080 fibrosarcoma, 143B PML 
BK TK and MG-63 osteosarcoma were grown as monolayers, where-
as U-937 histiocytic lymphoma, K-562 chronic myelogenous leuke-
mia, KG-1 acute myelogenous leukemia, JEG-3 choriocarcinoma, 
JAR placenta choriocarcinoma, MOLT-4 acute lymphoblastic leuke-
mia, Raij Burkitt lymphoma, and Jurkat lymphoma were grown in 
suspension. All cell lines were grown in Dulbecco's modified Eagle's 
medium as described before [8]. Within the panel of melanoma cell 
lines, 1F6 and 530 represent poorly metastasizing cell lines, with a 
metastasis frequency of less than 10% 3 months after subcutaneous 
inoculation into nude mice. The cell lines BLM and MV3 represent 
the highly metastatic phenotype, with over 50% metastasis frequency 
[3]. Excision and processing of the human tissues was performed as 
described before [9]. 
2.2. RNA isolation and Northern blot analysis 
Total RNA from human tissues and xenografts was isolated using 
the lithium-urea procedure as described by Auifray and Rougeon [10], 
whereas total RNA from cell lines was isolated using RNAzol solu-
tion (Tel-Test, Friendswood, TX). RNA oligo-deoxythymidine selec-
tions were performed using oligo-deoxythymidine columns (type II, 
Coll. Research, Bedford, MA). 10 ug of total RNA was glyoxylated 
[11], size fractionated on 1% agarose gels, and blotted onto Hybond 
N + (Amersham, Aylesbury, UK). To confirm that equal amounts 
were loaded in each lane, the blots were afterwards hybridized with 
an 18S ribosomal RNA probe. 
2.3. Construction of cDNA libraries 
A cDNA library was constructed from 5 ug of oligo-deoxythymi-
dine selected RNA from the poorly metastatic human melanoma cell 
line 530, using a XZap cDNA synthesis kit (Stratagene, La Jolla, CA) 
as described before [4]. 
2.4. DNA probes and hybridization 
DNA probes were radiolabeled by the random prime labelling 
method by Feinberg and Vogelstein [12]. Hybridization of cDNA 
library was performed according to standard protocols [13], 
2.5. DNA sequencing and computer analysis 
DNA fragments were sequenced according to the dideoxy method 
as described by Sanger et al. [14] using a Sequenase sequencing kit 
(USB, Cleveland, OH). Large fragments were sequenced by construct-
ing a set of deletion clones using exonuclease III (Erase-a-base kit, 
Promega, Madison, WI). Identification of known sequences was per-
formed using the EMBL/Genbank database [15,16]. DNA sequence 
analysis, including searches for motifs, alignments, and structure pre-
dictions, was performed using the CAMMSA programs MOTIFS, 
PILEUP, CLUSTAL V, BESTFIT, PEPTIDESTRUCTURE, PLOT-
STRUCTURE, and MEMBRANE PROPENSITY which are all part 
of the Wisconsin Package V 7.0 [15]. 
2.6. DNA isolation and Southern blot analysis 
Chromosomal DNA was isolated according to the method of Blin 
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Fig. 1. Northern blot analysis of a panel of human melanoma cell lines (A) and xenografts (B). Total RNA samples (10 ug) were loaded in 
each lane. Lane 1: BLM; lane 2: MV3: lane 3: 1F6; lane 4: 530. The blots were hybridized to radiolabeled 1.8 kb nmd cDNA insert of 
pJG454. The molecular weight marker was .^DNA digested with Hindlll. As a check of the amount of RNA loaded in each lane an 18S ribo-
somal RNA hybridization is shown. 
and Stafford [17]. DNA was digested with BamHI, and 10 ug was size 
fractionated on 0.6% agarose gels, transferred to Hybond N+ and 
hybridized as described previously for Northern blot analysis. To 
check for equal loading of DNA, the blot was hybridized afterwards 
to a chromosome 18-specific centromeric probe. No abnormalities 
involving chromosome 18 are known in relation with melanoma. 
3. Results 
3.1. Cloning and sequence analysis of nmd 
Using the differential mRNA display technique we isolated 
nine cDNA clones, which were differentially expressed in hu-
man melanoma cell lines. One of these clones, clone 6, repre-
senting a gene designated nmd, showed a unique expression of 
a 1.9 kb transcript in the poorly metastatic human melanoma 
cell lines 530 and 1F6, and derived xenografts, whereas ex-
pression was not detected in the highly metastatic human 
melanoma cell lines MV3 and BLM, and xenografts derived 
from these cell lines (Fig. 1). 
Screening of a cDNA library derived from cell line 530 
resulted in the isolation of the nmd cDNA clone pJG454. 
The nmd cDNA sequence consists of 1767 nucleotides 
(U37591 GenBank). The longest open reading frame starting 
with a methionine codon at position 27 in the nucleotide 
sequence encodes a 456 amino acids long polypeptide (not 
shown). 
Sequence analysis showed no identities with known genes or 
proteins, except for the 3' and 5' ends of a partially sequenced 
human cDNA clone 120969 with accession numbers T96131 
and T96213 respectively. Similarities at the protein level could 
be detected with human and several other lipases. This is 
illustrated by the alignment of NMD with five different hu-
man lipases (Fig. 2). The overall identity of NMD with differ-
ent human lipases is almost 30%. 
Hydrophobicity plot analysis of the predicted amino acid 
sequence of NMD revealed a hydrophobic leader peptide with 
a putative signal cleavage site located 25 amino acids down-
stream of the translation start (Fig. 2). Potential N-glycosyla-
tion sites are located at positions 54 and 340, protein kinase C 
phosphorylation sites at positions 259, 344 and 379, and ca-
sein kinase II phosphorylation sites at positions —3, 74, 162, 
175, 193, 244, 316 and 330. Furthermore a serine active site 
for lipase is located at position 141. 
3.2. Northern blot analysis of nmd in human melanocytic 
lesions 
Total RNA isolated from human melanocytic lesions was 
hybridized with the 1.8 kb nmd cDNA insert of pJG454 as a 
probe (Fig. 3). The expression of nmd mRNA could not be 
detected in normal skin (lane A) and three metastatic lesions 
(lanes K, L and M). A weak nmd expression was detected in 
cultured melanocytes (lane B), xenograft derived from radial 
growth phase (lane C) and vertical growth phase (lane D), and 
three metastatic lesions (lanes G, J and O), whereas expression 
was moderate to high in seven out of 13 metastatic lesions 
(lanes E, F, H, I, N, P and Q). 
3.3. Expression of nmd is restricted to a few human organs and 
tumor cell lines 
A Northern blot containing total RNA from gut, spleen, 
placenta, liver, muscle, lung, prostate, kidney cortex and 
kidney medulla was hybridized with the 1.8 kb nmd cDNA 
insert of pJG454 as a probe (Fig. 4). Expression of nmd 
was only detected in placenta (lane 3) and liver (lane 4). 
For further characterization a Northern blot containing 
total RNA from 17 different human tumor cell lines was 
screened with the nmd cDNA insert. No expression was 
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nmd MPPGPWESCF WVGGLILWLS VGSSG 
hPL L LWTL LL LGAVAG- / / 
hPLRPl LIFWTITLE LL AAKG / / 
hPLRP2 L PWTLGLL LLATVRG / / 
hHL DTS LCFSI LLVLC FIQS SAL 
hLPL ESKALLVLT LAVY QSLTA SRGGVAA 
/ / DAPPT PQPKCADFQS ANLFEGTDLK V QFLLFV PSNPSCGQLV 
KEV CYERLGCFSD DS WSGITER PLHILPWSP DVNTR YT NE NNF E 
KEV CYEDLGCFSD TE WGGTAIR PLKILPWSPE KIGTR YT NE NNF IL 
KEV CYGQLGCFSD EKPWAGTLQR PVKLLPWSPE DIDTR YT NE NNF I 
/ / GQSLK E FGRR QAVE T KTLHEMK- TR G ET -QGC IR 
/ / ADQ RRDFIDIES- -K A RT PEDTAEDTCH 
42 
53 
53 
53 
42 
28 
nmd EG--SSDLQN -SGFNATLGT KLIIHGFRVL GTKPSWIDTF IRTLLRA--T 
hPL AADS ISGS --N KTNRK RF 
hPLRPl LLSDP TIEA - N QMDRK RF 
hPLRP2 TGTEPDTIEA - N QLDRK RF 
hHL INHPDTLQEC -- SS PL VM 
hLPL LIPGVAESVA TCH HSSK FMV 
-ID KGEEN LANV CRN FKV--E 
-ID KGDE VTDM CKK FEV--E 
-LD KAED PSDM CKKMFEV--E 
WS D VLEN WQM VAA KSQPAQ 
WT T MYE VPKL VAA YKREPD 
NA1 
SV 
EV 
KV 
PV 
S-
IVIAVI 
C C 
C C 
C C 
GL 
V 
)WI 
K 
K 
R 
L 
YGSTGVYFSA 
G RTG TQ 
K QAT TQ 
H RAM TQ 
TLAHDH TI 
SRAQEH PVS 
VKNVIKLSLE 
SQ IRIVGA 
AN RWGAQ 
Q IRWGA 
R TRLVGK 
AGYTKLVGQD 
117 
128 
129 
129 
120 
107 
****** ***** 
nmd 
* ********* * * * *** *** *** 
ISLFLNKLLV -LGVSESSIH IIGVSLGAHV GGMVGQLFGG Q-
hPL VAY VEF QS AF Y P NV V H 
hPLRPl VAQM DI T EYSYPP KV L H 
hPLRP2 TAFLIQA ST Q Y LEDV V H 
hHL VAAL RW EE SVQL R HV L Y 
hLPL VAR I WMEE EFNYPLDNV LL Y 
A A EA RRTN T I R 
A EA SKTP - SR 
T AAEA RRL - RV R 
V S FA SSI THKI R 
A A IA S --T NKKVNR 
E CFQGT PELV 
VEASFEST PE V 
CFQDE PE V 
A LFEGS APSN 
NFEY EAPS 
.DAGD 
PS 
PS 
PS 
SPD 
SPD 
ALFVEAIHTD 
K 
D 
V 
S 
D 
DV 
DV 
DV 
D F 
DVL F 
194 
206 
20S 
207 
200 
185 
****** ***** ********* *** *** *** 
******* ***** nmd 
hPL 
hPLRPl 
hPLRP2 
hHL 
hLPL 
TD NL 
GAPIVPNLGF 
AAPLIPFLGF 
SSPIVPSLGF 
REHMG LSV 
RGSPG RSI 
GIRIPVGHVD YFVNGGQDQP GC PTFFYAG 
MSQV L F P VEM 
TNQQM L F P ESM 
MSQK L F P KEM 
KQ I Y FYP SF 
QK IYP TF 
* ************ * 
KKNILSQI VDIDGIWEGT 
KKNALSQI VDLDGIWAGT 
KKNVLSTI TDIDGIWEGI 
HFLELYRH IAQHG- N I 
NIGEAIRV IAERGL-GDV 
YSYLICDHMR 
RDFAA N L 
RDFVA N L 
GGFVS N L 
TQTIK S E 
DQLVK S E 
AVHLYISALE 
SYKY TDSIV 
SYKY LESIL 
SFEY S SVL 
S F DS L 
SI F DS L 
* * *** * ** 
NSCPLM-AFP 
PDGFA G 
PDGFA Y 
PDGFL GY 
HAGTQSM Y 
EENPSK YR 
* ** 
256 
285 
285 
286 
278 
263 
nmd 
hPL 
hPLRPl 
hPLRP2 
hHL 
hLPL 
CASYKAFLAG RCLDCFNPFL LSCPRIGLVE QGGVKIEPLP KEVKVYLLTT SSAPYCMHHS LVEFHLKELR NKDTNIEVT-
NV T N K FP PSG-
T S ESD K FP PDQ-
DE QES K FP PDE-
GDMNS SQ L S KKG-
S KE EK L S RKN-
-DRYPGKTND VGQ F D G DASNFARWRY K SVT SGKK VTGHILVSL-
-DKFAGRTSE EQQ FF N G EASNFARWRY G SIT SGRT ATGQIKVAL-
-G QM HYA 
-G QM HYA 
-G KM HYA -DQF GKTSA V QTFF N G ESGNFTSWRY K SVT SGKE KVNGY RIAL 
-R NTL YHV RQEPRSKS-- --KRLF V R AQS FKVY Y QLKIQF-INQ TETPIQTTFT 
-S M K R QM KVF Y Q KI FSGTE SETHTNQAFE -R NNL YE I NKVRAKRS-
335 
360 
360 
362 
350 
336 
nmd 
hPL GNKGN-
hPLRPl GNKGN 
hPLRP2 YG NEN-
hHL MSLLGTKE--
FLSSNIT SSSKITIPKQ QRYGKGII--
YEIF TL--
H YSIFR L--
YEIF SL--
M 
-AHATPQCQI NQVKFKFQSS NRV WKKD 
-KPDSTHSNE FDSDVDVGDL QM KFI Y-N NV-
-KPGSTHSYE FDA LDVGTI EK KFL -NN NV-
-KPDASHTCA ID D NVGKI QK KFL -NK RG-
-R TTII-
-I NPTL-
-I NPTL-
-I NLSE-
KIPITLGKG IASNKTYSFL ITLDVDIGEL IMIKFK ENS AVWANVWDTV Q PWSTGP 
hLPL ISLYGTVA-- ES ENIPFTLPE- VSTNKTYSFL IYTEVDIGEL LMLKLK KSD SYFS--WSD- WWSSP 
* * ***** *** * 
391 
412 
412 
414 
420 
397 
nmd 
hPL 
hPLRPl 
hPLRP2 
hHL 
hLPL 
--GKFCTALL 
--PRVGASKI 
--P VGATKI 
--P LGASQI 
RHSGLVLKTI 
GFAIQKI 
PI 
I 
T 
T 
R 
R 
7NDREKM 
ETNVG-
QKG E-
QSG D-
KAG T-
KAG T-
-K-QF FCSP E REEV LT LTPC 
-KTVY FCSE D RE T LT LTPC 
-GTEY FCS D EENV QS LYPC 
-QQRMTFCSE N --D L LR PTQEKIFVKC EIKSKTSKRK IR 
-QKK IFCSR EK --SH QK GKAPAVFVKC HDKSLNKKSG 
426 
449 
450 
452 
476 
448 
Fig. 2. Alignment of the predicted protein NMD with the other human lipases (hPL: human pancreatic lipase; hPLRPl: human pancreatic li-
pase-related protein 1; hPLRP2: human pancreatic lipase related protein 2; hHL: human hepatic lipase; hLPL: human lipoprotein lipase). 
Published sequences of other human lipases [28-32] are compared with our sequence. The alignment starts with the leader peptide and the 
cleavage sites are indicated by slashes (/ /). Numbering starts from the first amino acids of the mature products. Identical amino acids are indi-
cated by empty spaces, amino acid deletions by dashes (-). Conservation of amino acids is indicated by an asterisk (*) above and below the se-
quences; bold in the case of a conservation in at least five out of six sequences. See text for further details. 
found in cell lines derived from carcinomas of the prostate, 
cervix and breast or from choriocarcinoma, epidermoid carci-
noma, lymphoma and myeloid leukemia. In T24 cells (bladder 
carcinoma) and Caco-2 cells (colon carcinoma), the 1.8 kb 
nmd transcript was only detected at low levels (results not 
shown). 
4. Discussion 
This paper describes the characterization of nmd, a novel 
gene, expressed in two melanoma cell lines with a low meta-
static potential and in xenografts derived from these cell lines. 
Expression was absent in two highly metastatic cell lines and 
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Fig. 3. Northern blot analysis of human cutaneous lesions. Total RNA samples (10 u.g) were loaded in each lane. Lane A: normal skin (13 bi-
opsies from 12 patients); lane B: melanocytes; lane C: xenograft derived from radial growth phase; lane D: xenograft derived from vertical 
growth phase; lanes E-Q: melanoma metastatic lesions. The blot was hybridized to radiolabeled 1.8 kb nmd cDNA insert of pJG454. The mo-
lecular weight marker was XDNA digested with HindlR. As a check of the amount of RNA loaded in each lane an 18S ribosomal RNA hy-
bridization is shown. Densitometric scanning showed that the maximum variation in 18S rRNA loading (between lanes K and C) was not 
more than 3-fold, whereas this was 50-fold for nmd mRNA (between lanes N and G, lanes A, K, L and M being negative). 
derived xenografts (Fig. 1). The differences in nmd mRNA 
expression between poorly and highly metastasizing melano-
ma cell lines cannot be ascribed to gene amplification or other 
major chromosomal rearrangements, as demonstrated by 
Southern blot analysis (results not shown). 
Sequence analysis revealed that nmd is a novel gene encod-
ing a 50 kDa protein, which probably represents a new mem-
ber of the enzyme family of lipases [5,18,19]. The similarity 
with other lipases is sufficiently high to classify NMD as an a/ 
(3-hydrolase-fold enzyme [20,21]. Amino acid residues 135-145 
(IHIIGVSLGAH), centered around Ser-141, are completely 
homologous to the consensus for the active site of lipases 
(Fig. 2). Beside Ser-141, NMD also contains two other active 
site residues (Asp-165 and His-235) and the oxyanion residue 
Phe-66. When compared to other human lipases, NMD is 
characterized by a deletion of 11 amino acids between Cys-
220 and Pro-221. The deleted sequence constitutes a large part 
of the so-called lid domain of the other lipases (Fig. 2). The 
lid domain or 'flap' regulates access to the active site of the 
classical pancreatic lipase [19]. A similar deletion is present in 
guinea pig pancreatic (phospho)lipase GPLRP2 and in phos-
pholipase Al from hornet venom (Dolml), two other member 
of the lipase family [6]. In the absence of an aggregated lipid 
substrate, the lid domain prevents access to the active site. In 
the presence of water-insoluble substances, the lid domain as 
well as another surface loop (the so-called (35 loop) undergo 
large conformational changes thus opening access to the ac-
tive site and creating the oxyanion hole [5,19,21]. In GPLRP2, 
containing a 'mini-lid', the catalytic site is freely accessible, 
and it displays a high phospholipase activity [5,6]. In the pan-
creatic (phospho)lipase of the coypu (coypu pancreatic lipase-
related protein 2 or CoPLRP2), the lid domain is not deleted, 
but the stabilizing interactions observed in classical pancreatic 
lipase between the lid domain, the protein core and the (35 
loop, are missing. The observed similarities suggest that NMD 
represents a new branch in the gene family of lipases and 
possesses an inherent phospholipase activity. 
During evolution guinea pig and coypu, both South Amer-
ican rodents, have lost the metabolic enzyme phospholipase 
A2 [22,23]. It is speculated that the atypical substrate specific-
ity of GPLRP2 and CoPLRP2, caused by a deletion in the lid 
domain, compensates for this loss [6,24]. Our discovery of 
nmd in the human genome indicates that the use of a 'lid-
less' lipase is not confined to a few exceptional species. 
Among the cell lines and tissues tested expression of nmd 
was restricted to some human melanoma cell lines and lesions, 
as well as to human liver and placenta and, only at low levels, 
to the tumor cell lines T24 and Caco-2. The expression pro-
files of nmd mRNA in human melanoma cell lines and derived 
xenografts suggest it to be a potential marker for early stages 
of melanoma progression. Its presence, however, in a consid-
erable number of human melanoma metastatic lesions seems 
to be in contrast with this suggestion. It is remarkable that 
other potential early progression markers, notably «TO23 [25], 
nma [26] and nmb [27] display a similar expression distribu-
tion. Genes like wm23, nma, nmb and also nmd may be in-
volved in attenuating metastatic properties of melanoma cells, 
possibly as a consequence of tumor-host interactions. Tumor 
progression may require that genes are (temporarily) switched 
off in the course of metastasis, but sometimes turned on again 
later in a secondary, distantly growing tumor [4,26]. 
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